OakChart

Nektar Therapeutics

NKTRHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 11:37 AM ET

38.81+1.03 (2.73%)
2026-11-11 17:38 CET
Market cap
1,289.92 USD m
Revenue, TTM
54.59 USD m
Net income, TTM
-157.13 USD m
Free cash flow, TTM
-234.03 USD m
EPS diluted, TTM
-6.70
P/E
-
Compare

Price

NKTR against its 20, 50 and 200-day averages
2050200beatearnings
40.0060.0080.003.1M6.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NKTRclose 38.8120-day 37.8350-day 49.97200-day 65.0438.8152w low

64.4% under the 52-week high of 109.00 on 20 Apr 2026. 52-week low 33.40 on 30 Jan 2026. Last 15 sessions, 11.5% high to low

Profile

NKTR
52-week range, 7% of the way up
33.40109

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

IndexRUT
Employees63
IPOMay 03, 1994
Beta1.42
ATR, 14d2.09
Rel volume0.31
Short float20.47%
Insider own3.21%
Inst own104.01%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.33B
Enterprise Value776.68M
Income-157.13M
Sales54.59M
Book/sh26.46
Cash/sh20.04
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees63
IPOMay 03, 1994

Ratios

P/E-
Forward P/E-
PEG-
P/S24.27
P/B1.47
P/C1.94
P/FCF-
EV/EBITDA-
EV/Sales14.23
Quick Ratio10.42
Current Ratio10.42
Debt/Eq0.15
LT Debt/Eq0.13
Option/ShortYes / Yes

Earnings

EPS (ttm)-6.70
EPS next Y-10.50
EPS next Q-2.07
EPS this Y16.92%
EPS next Y-29.95%
EPS next 5Y-3.29%
EPS past 3/5Y30.93% 23.59%
Sales past 3/5Y-15.66% -18.43%
EPS Y/Y TTM23.10%
Sales Y/Y TTM-27.15%
EPS Q/Q58.38%
Sales Q/Q-9.34%
EarningsNov 12 AMC
EPS/Sales Surpr.37.60% -2.82%

Ownership

Insider Own3.21%
Insider Trans-2.88%
Inst Own104.01%
Inst Trans28.94%
ROA-24.12%
ROE-35.75%
ROIC-15.46%
Gross Margin98.73%
Oper. Margin-239.32%
Profit Margin-287.84%
SMA202.60%
SMA50-22.34%
SMA200-40.33%
Trades-

Technical

Shs Outstand34.13M
Shs Float33.05M
Short Float20.47%
Short Ratio6.21
Short Interest6.77M
52W High109.00 -64.39%
52W Low33.40 16.20%
Volatility4.90% 4.58%
ATR (14)2.09
RSI (14)42.10
Beta1.42
Rel Volume0.31
Avg Volume1.09M
Volume121,029

Performance

Perf Week0.86%
Perf Month2.35%
Perf Quarter-48.88%
Perf Half Y-48.90%
Perf YTD-8.21%
Perf Year-34.51%
Perf 3Y468.77%
Perf 5Y-80.91%
Perf 10Y-82.04%
Recom1.53
Target Price133.08
Prev Close37.78
Price38.81
Change %2.73%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedUUBSNeutral$53+36.6%
Oct 12, 2026InitiatedLLeerink PartnersOutperform$130+235.0%
Oct 09, 2026InitiatedRRaymond JamesMkt Perform
Aug 21, 2026ResumedJJP MorganNeutral$65+67.5%
Jul 22, 2026InitiatedCCanaccord GenuityBuy$153+294.2%
Mar 24, 2026InitiatedWWedbushNeutral$70+80.4%
Mar 17, 2026InitiatedTTD CowenBuy
Feb 10, 2026UpgradeWWilliam BlairMkt Perform → Outperform
Nov 26, 2025InitiatedCCitigroupBuy$102+162.8%
Jun 24, 2025ReiteratedHH.C. WainwrightBuy$6.50 → $120+209.2%

Peers

Mkt cap
TickerCompanyMkt cap
ATTOAttovia Therapeutics Inc783.52M
EVMNEvommune Inc318.64M
QTTBQ32 Bio Inc280.54M
KYMRKymera Therapeutics Inc11.53B
MANEVeradermics Inc6.33B
ORKAOruka Therapeutics Inc7.30B
REGNRegeneron Pharmaceuticals Inc94.67B
ARQTArcutis Biotherapeutics Inc3.54B
IMCRImmunocore Holdings plc ADR1.63B
COYACoya Therapeutics Inc76.01M

Insider trading

latest 14 of 29
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Zalevsky JonathanChief R&D OfficerAug 18 '26Sale71.9818613,3889,570Aug 20 07:05 PM
ROBIN HOWARD WPresident & CEOAug 18 '26Sale71.9841830,08854,627Aug 20 07:03 PM
Zalevsky JonathanOfficerAug 18 '26Proposed Sale71.9818613,388Aug 18 03:57 PM
ROBIN HOWARD WOfficerAug 18 '26Proposed Sale71.9841830,087Aug 18 03:42 PM
Zalevsky JonathanChief R&D OfficerJun 30 '26Sale70.005,681397,6709,756Jul 02 07:06 PM
JONATHAN ZALEVSKYOfficerJun 30 '26Proposed Sale65.395,681371,481Jun 30 04:36 PM
ROBIN HOWARD WPresident & CEOJun 17 '26Sale61.1910,000611,88055,045Jun 18 07:08 PM
ROBIN HOWARD WPresident & CEOJun 16 '26Sale60.3210,000603,17665,045Jun 18 07:08 PM
Zalevsky JonathanChief R&D OfficerJun 15 '26Sale60.715,538336,21215,437Jun 17 07:12 PM
ROBIN HOWARD WOfficerJun 17 '26Proposed Sale60.2710,000602,700Jun 17 11:05 AM
ROBIN HOWARD WOfficerJun 16 '26Proposed Sale60.9610,000609,600Jun 16 11:07 AM
JONATHAN ZALEVSKYOfficerJun 15 '26Proposed Sale59.385,538328,846Jun 15 04:56 PM
Zalevsky JonathanChief R&D OfficerMay 19 '26Sale65.5119913,03620,975May 21 06:26 PM
ROBIN HOWARD WPresident & CEOMay 19 '26Sale65.5144429,08675,045May 21 06:26 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 391.13M

News

latest 14 of 206
  • Nektar Reports With Shares Halved, Phase 3 Spending Rising And A Jury Trial To Explain (Earnings Whispers) -6.06%
  • Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets (PR Newswire)
  • Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
  • EADV26: Key late-stage readouts from the conference (Clinical Trials Arena)
  • Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating. (Investor's Business Daily) -22.39% -7.26%
  • Loading…
  • NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge (Stocktwits)
  • Nektar Stock Sinks Despite Promising Hair Loss Treatment Data (Barrons.com)
  • 3 Biotech Stocks Put Traders Are Targeting Today (Schaeffer's Research)
  • New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 (PR Newswire)
  • New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis (PR Newswire)
  • Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 (PR Newswire) +5.85%
  • Eli Lilly Wins FDA Approval for Weekly Insulin. Heres What Comes Next (TIKR)
  • A Jury Awarded Nektar $90 Million From Eli Lilly. Heres Why the Stock Barely Moved (TIKR)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--2.069--10.2715
2026Q22026-08-13-1.230-1.971-1.23010.1310.4311
2026Q12026-05-07-1.820-1.582-1.81510.8610.699
2025Q42026-03-12-1.780-2.474-1.77821.8110.198
2025Q32025-11-06-1.870-2.685-1.87511.7910.058
2025Q22025-08-07-2.950-3.028-2.95311.189.498
2025Q12025-05-08-3.600-2.564-3.61910.4615.358
2024Q42025-03-120.450-2.0340.51029.1835.5010
2024Q32024-11-07-2.700-2.985-2.65724.1219.188
2024Q22024-08-08-3.750-2.775-3.76123.4920.816
2024Q12024-05-09-2.850-2.850-2.83521.6415.343
2023Q42024-03-04-3.300-3.156-3.30423.8921.436
2023Q32023-11-07-3.600-2.975-3.61124.1421.267
2023Q22023-08-08-4.050-4.223-4.04320.5021.798
2023Q12023-05-09-10.950-3.720-10.88221.5919.417
2022Q42023-02-28-4.800-6.779-4.75622.0222.1410

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-37.800-37.784-37.773114.62108.26
2020FY-37.350-37.500-37.331152.92159.25
2021FY-42.900-43.437-42.868101.91111.04
2022FY-29.550-31.893-29.51392.0691.46
2023FY-21.750-21.612-21.79490.1284.89
2024FY-8.700-10.751-8.67798.43104.74
2025FY-9.730-9.927-9.73055.2343.55
2026FY--8.084--41.82
2027FY--10.504--53.42
2028FY--10.724--38.45
2029FY--9.387--46.59
2030FY--5.273--177.57

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-28151110.279.5411.00
2026Q3S2026-10-09151710.279.5411.00
2026Q3S2026-10-07131710.319.5411.00
2026Q3S2026-10-01121710.269.5411.00
2026Q3S2026-09-30121710.269.5411.00
2026Q3S2026-09-29121710.389.5412.00
2026Q3S2026-08-20122610.419.5412.00
2026Q3S2026-08-18112610.459.5412.00
2026Q3S2026-08-14112610.459.5412.00
2026Q3S2026-08-13100110.206.0011.30
2026Q3S2026-08-05100110.206.0011.30
2026Q3S2026-08-04100110.216.0011.30
2026Q3S2026-07-27100110.206.0011.30
2026Q3S2026-07-22100210.206.0011.30

Estimate history

EPS, annual-9.356.739-37.773-37.331-42.868-29.513-21.794-8.677-9.725-6.6967
Period201720182019202020212022202320242025TTM
EPS, quarterly-3.761-2.6570.51-3.619-2.953-1.875-1.778-1.815-1.229
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual307.7111193.323114.617152.915101.90792.05590.12298.42755.23254.59
Period201720182019202020212022202320242025TTM
Sales, quarterly23.48924.12429.17510.4611.17511.7921.80710.86110.131
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual10.63511.56911.76712.00612.36512.57112.75912.38520.37934.13
Period201720182019202020212022202320242025MRQ
Shares, quarterly12.27112.29712.38512.40712.45719.65320.37920.37934.13
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue54.5955.2398.4390.1292.06101.91152.91114.621,193.32
Cost of Goods Sold Incl. D&A0.691.0331.9536.6429.1434.7228.7429.5229.98
Gross Profit53.9054.2166.4753.4862.9267.19124.1785.101,163.34
Selling, General and Administrative Excl. Other184.54188.68199.59190.90303.15513.29504.10525.13475.41
Research and Development131.74117.07119.64111.29210.82390.45399.42426.42393.97
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-130.64-134.47-133.12-137.43-240.24-446.10-379.92-440.04687.93
Interest Expense30.9626.1828.1125.3328.9147.3137.1246.3542.78
Unusual Expense10.099.3315.67128.46102.5032.4345.190.000.00
Net Income Before Taxes-153.11-155.49-119.20-276.26-364.98-523.28-443.95-440.05682.73
Income Taxes0.06-0.14-0.24-0.203.210.560.490.611.41
Consolidated Net Income-157.13-164.08-118.96-276.06-368.20-523.84-444.44-440.67681.31
Net Income From Continuing Operations-157.13-164.08-118.96-276.06-368.20-523.84-444.44-440.67681.31
Net Income-157.13-164.08-118.96-276.06-368.20-523.84-444.44-440.67681.31
EPS (Recurring)-4.54-9.34-7.88-14.69-23.76-41.01-34.67-37.7756.74
EPS (Basic, Before Extraordinaries)-6.70-9.73-8.68-21.79-29.51-42.87-37.33-37.7760.26
EPS (Diluted)-6.70-9.73-8.68-21.79-29.51-42.87-37.33-37.7756.74
EBITDA-129.95-133.44-128.73-129.61-228.04-433.10-367.42-429.04696.73
Non-Operating Income (Expense)18.5814.5057.7014.966.672.5718.2846.3437.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.129.9917.0726.3845.2869.1168.8172.8569.60
Price To Earnings Ratio--------9.10
Price To Sales Ratio42.2712.911.941.194.5924.3019.8532.964.96
Gross Margin98.7398.1467.5459.3468.3565.9381.2174.2597.49
Operating Margin-239.32-243.47-135.25-152.49-260.97-437.76-248.45-383.9257.65
Net Margin-287.84-297.07-120.86-306.31-399.98-514.03-290.65-384.4757.09
Shares Outstanding34.1320.3812.3912.7612.5712.3612.0111.7711.57
Market Capitalization1,289.921,289.92172.77107.79424.782,505.673,061.553,809.865,703.93

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue10.1310.8621.8111.7911.1810.4629.1824.12
Cost of Goods Sold Incl. D&A0.160.150.190.200.210.437.984.43
Gross Profit9.9710.7121.6211.5910.9610.0321.2019.69
Selling, General and Administrative Excl. Other51.7448.9740.7143.1346.7454.4045.8853.99
Research and Development39.1335.6829.6827.2529.8930.4828.7435.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-41.76-38.26-19.09-31.53-35.78-44.37-24.68-34.30
Interest Expense7.217.949.776.055.394.9710.156.02
Unusual Expense0.580.808.570.140.450.171.360.05
Net Income Before Taxes-40.30-43.09-34.70-35.02-39.40-46.377.00-37.05
Income Taxes0.000.060.03-0.03-0.190.05-0.260.01
Consolidated Net Income-40.62-44.90-36.08-35.52-41.59-50.887.26-37.06
Net Income From Continuing Operations-40.62-44.90-36.08-35.52-41.59-50.887.26-37.06
Net Income-40.62-44.90-36.08-35.52-41.59-50.887.26-37.06
EPS (Recurring)-1.22-1.79-1.48-1.87-2.93-3.610.58-2.65
EPS (Basic, Before Extraordinaries)-1.23-1.82-1.78-1.87-2.95-3.620.52-2.66
EPS (Diluted)-1.23-1.82-1.78-1.87-2.95-3.620.51-2.66
EBITDA-41.61-38.11-18.90-31.34-35.57-43.94-24.35-33.31
Non-Operating Income (Expense)9.253.912.732.702.233.1443.203.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.662.654.392.432.753.083.794.26
Price To Sales Ratio42.2731.9915.5417.224.861.642.022.92
Gross Margin98.4698.6199.1398.3498.0995.9372.6581.62
Operating Margin-412.23-352.25-87.54-267.45-320.21-424.15-84.60-142.18
Net Margin-400.97-413.44-165.45-301.29-372.20-486.4424.89-153.61
Shares Outstanding34.1320.3820.3819.6512.4612.4112.3912.30
Market Capitalization1,289.922,064.10860.041,082.16320.59126.55172.77239.80

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments245.75255.23303.62504.98733.961,061.901,324.861,335.35296.13
Short Term Receivables1.781.612.255.9823.8943.9936.8043.215.01
Inventories0.000.0016.1019.2015.8019.2044.5037.8310.73
Other Current Assets18.734.468.7315.8121.9312.9215.3921.2914.95
Total Current Assets266.27261.29330.70545.97795.581,138.011,421.551,437.69326.82
Net Property, Plant & Equipment5.0011.8236.8685.89177.53186.14199.1848.8547.46
Total Investments and Advances3.4926.0925.820.0064.83136.66279.12582.8957.09
Intangible Assets-0.000.0076.5076.5076.5076.5076.5076.50
Other Assets5.654.654.642.252.741.461.014.240.99
Total Assets280.41303.85398.03710.601,117.191,538.771,977.362,150.17508.87
Short Term Debt Incl. Current Port. of LT Debt20.5019.8719.2618.6717.4413.91261.210.000.00
Accounts Payable10.7711.569.8512.989.7522.1419.235.854.78
Other Current Liabilities22.2729.9722.1636.5658.0179.7273.4576.1551.38
Total Current Liabilities53.5461.4051.2768.2085.20115.78353.8982.0056.16
Long Term Debt128.41174.47211.14239.30273.85306.45189.71308.67320.99
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities8.627.244.6336.4678.6339.2528.3741.9343.88
Total Liabilities190.57243.11267.05343.96437.68461.47571.97432.60421.04
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity89.8360.74130.99366.64679.511,077.301,405.391,717.5887.83
Total Shareholders Equity89.8360.74130.99366.64679.511,077.301,405.391,717.5887.83
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity89.8360.74130.99366.64679.511,077.301,405.391,717.5887.83
Total Liabilities & Stockholders Equity280.41303.85398.03710.601,117.191,538.771,977.362,150.17508.87
Book Value Per Share4.414.9010.2729.1754.9689.73119.43148.478.26
Tangible Book Value Per Share4.414.9010.2723.0848.7783.36112.93141.861.07
Full-Time Employees6361137216740718723618509
Price to Book Ratio1.432.840.681.033.692.842.713.32111.37
Return on Assets-56.17-33.90-49.80-40.29-39.45-25.28-21.3551.25-17.94
Return on Equity-217.94-124.10-110.95-70.39-59.64-35.80-28.2275.47-109.91
Return on Invested Capital-75.18-50.58-80.69-60.77-54.95-32.12-27.6333.62-23.65
Quick Ratio4.974.266.147.729.159.663.8917.075.63
Current Ratio4.974.266.458.009.349.834.0217.535.82

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-157.13-164.08-118.96-276.06-368.20-523.84-444.44-440.67681.31
Depreciation0.691.034.397.8213.0314.1514.1813.1610.87
Other Funds (Non Cash)-11.50-8.45-54.9095.5847.96120.11100.2677.1465.04
Funds from Operations-167.94-171.50-169.47-172.81-304.50-389.58-330.00-350.37757.22
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-65.85-37.02-6.24-19.800.49-23.0816.7121.69-39.01
Cash from Operating Activities-233.79-208.51-175.71-192.61-304.01-412.66-313.29-328.68718.21
Capital Expenditures-0.24-0.17-1.47-0.86-5.68-14.99-7.26-26.29-14.24
Net Assets From Acquisitions-0.70-0.700.000.000.000.000.00--
Sale of Fixed Assets and Businesses0.000.0065.391.2513.200.000.000.002.63
Purchase or Sale of Investments-844.16-0.3378.65139.18358.31217.77503.47233.17-1,368.33
Purchase of Investments-1,228.87-285.01-261.71-511.70-467.91-960.69-987.53-1,380.87-2,271.25
Sale Or Maturity of Investments384.71284.68340.36650.88826.231,178.451,491.001,614.04902.92
Other Uses0.700.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-844.40-1.20142.57139.56365.83202.78496.21206.89-1,379.94
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1,074.47180.5727.120.030.7633.2423.4023.36851.97
Repurchase of Common Pref Stock0.000.00-3.000.000.000.000.000.000.00
Sale of Common Pref Stock1,074.47180.5730.120.030.7633.2423.4023.36851.97
Proceedsfrom Stock Options1,073.82179.700.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.0015.000.000.000.00-103.750.000.00
Change in Long Term Debt0.000.0015.000.000.000.00-103.750.000.00
Issuance of Long Term Debt0.000.0015.000.000.000.00146.250.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-250.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.753.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities1,074.47180.5742.120.031.5136.24-80.3523.36851.97
Exchange Rate Effect0.000.01-0.000.06-0.33-0.090.02-0.10-0.10
Net Change in Cash-3.72-29.148.97-52.9563.01-173.74102.59-98.54190.14
Free Cash Flow-234.03-208.68-177.18-193.47-309.68-427.65-320.55-354.97703.98
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--------8.41
Deferred Taxes & Investment Tax Credit-0.000.00-0.142.710.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments684.34568.60245.75270.21175.90218.63
Short Term Receivables4.763.601.781.291.351.71
Inventories0.000.000.000.000.000.00
Other Current Assets50.3016.8418.739.869.319.57
Total Current Assets739.40589.04266.27281.36186.57229.91
Net Property, Plant & Equipment4.264.725.0010.0010.5711.16
Total Investments and Advances340.48164.733.494.845.379.78
Other Assets10.984.785.655.165.025.39
Total Assets1,095.13763.27280.41301.35207.53256.24
Short Term Debt Incl. Current Port. of LT Debt22.7122.5320.5022.1822.0121.84
Accounts Payable24.8910.0310.7715.5614.2817.83
Other Current Liabilities23.3925.1522.2728.5935.1031.25
Total Current Liabilities70.9857.7153.5466.3471.3970.93
Long Term Debt113.23120.90128.41144.90154.72164.82
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities7.798.458.625.035.646.76
Total Liabilities192.01187.06190.57216.26231.75242.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity903.12576.2289.8385.09-24.2113.74
Total Shareholders Equity903.12576.2289.8385.09-24.2113.74
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity903.12576.2289.8385.09-24.2113.74
Total Liabilities & Stockholders Equity1,095.13763.27280.41301.35207.53256.24
Book Value Per Share26.4628.284.414.33-1.941.11
Tangible Book Value Per Share26.4628.284.414.33-1.941.11
Full-Time Employees--63---
Price to Book Ratio1.4316.329.77-29.2823.349.21
Return on Assets-24.12-31.01-56.17-39.63-44.39-40.79
Return on Equity-35.75-53.60-217.94-180.24-440.80-189.46
Return on Invested Capital-4.00-6.44-16.53-15.45-31.87-28.50
Quick Ratio10.4210.214.974.242.613.24
Current Ratio10.4210.214.974.242.613.24

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-40.62-44.90-36.08-35.52-41.59-50.88
Depreciation0.160.150.190.200.210.43
Other Funds (Non Cash)-2.810.52-5.95-3.27-0.781.55
Funds from Operations-43.28-44.23-41.84-38.60-42.16-48.91
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-32.49-0.07-23.12-10.16-3.58-0.15
Cash from Operating Activities-75.77-44.30-64.96-48.76-45.74-49.05
Capital Expenditures-0.09-0.02-0.02-0.11-0.04-0.00
Net Assets From Acquisitions0.000.00-0.700.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-399.02-350.770.39-94.7649.6544.39
Purchase of Investments-535.45-452.25-91.60-149.56-18.92-24.93
Sale Or Maturity of Investments136.44101.4891.9954.8068.5769.32
Other Uses0.000.000.700.000.00-0.70
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-399.11-350.790.37-94.8749.6243.69
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock364.57529.5538.67141.680.210.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock364.57529.5538.67141.680.210.01
Proceedsfrom Stock Options364.57529.5538.26141.440.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities364.57529.5538.67141.680.210.01
Exchange Rate Effect0.000.000.000.000.01-0.00
Net Change in Cash-110.31134.46-25.92-1.964.09-5.36
Free Cash Flow-75.86-44.32-64.98-48.88-45.77-49.05

Revenue breakdown

License Collaboration And Other2024: 597.00K 2025: 300.00K
Non Cash Royalty Revenue Related To Sale Of Future Royalties2024: 64.27M 2025: 54.93M
Product2024: 33.56M
Non-US2024: 97.05M 2025: 55.23M
United States2024: 1.38M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3020.47%6.8M33.1M1.09M
2026-10-1521.17%7.0M33.1M1.11M
2026-09-3021.08%7.0M33.1M927.72K
2026-09-1517.35%5.7M33.1M859.00K
2026-08-3118.36%6.1M33.1M899.56K
2026-08-1418.67%6.2M33.0M965.58K
2026-07-3119.31%6.3M32.6M998.39K
2026-07-1520.89%6.8M32.6M1.17M
2026-06-3021.13%6.9M32.6M1.12M
2026-06-1515.16%4.9M32.6M999.66K
2026-05-2914.15%4.6M32.6M994.69K
2026-05-1513.40%4.4M32.6M1.03M
2026-04-3012.62%4.1M32.5M1.27M
2026-04-1512.50%3.6M29.0M1.10M
2026-03-3113.29%3.7M27.6M1.12M
2026-03-1313.32%3.7M27.6M1.19M
2026-02-2712.44%3.3M26.9M1.12M
2026-02-1317.86%3.5M19.5M1.05M
2026-01-3016.40%3.3M20.0M797.66K
2026-01-1516.29%3.3M20.0M838.62K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call25.0011.8015.100.002.8150.000.000.928-0.1050.008
call26.0010.8014.200.002.7120.000.000.923-0.1030.009
call27.009.8013.200.002.5280.000.000.917-0.1010.009
call28.008.9012.000.002.2320.000.000.910-0.0980.010
call29.007.9011.200.002.1770.000.000.903-0.0960.011
call30.006.9010.306.702.19014.000.000.893-0.0930.011
call31.006.009.500.002.0650.000.000.826-0.1610.016
call32.005.008.400.001.7960.000.000.812-0.1550.017
call33.004.107.600.001.7590.000.000.788-0.1560.018
call34.003.206.800.001.6870.000.000.749-0.1730.019
call35.002.505.605.301.41277.000.000.697-0.2160.021
call36.001.854.603.201.22150.000.000.668-0.2090.022
call37.001.154.702.101.4817.000.000.629-0.2250.023
call38.000.654.202.921.53112.000.000.591-0.2280.024
call39.000.303.301.751.40436.000.000.540-0.2130.024
call40.000.852.401.001.20398016.000.487-0.1880.024
call41.000.153.201.311.31346.000.000.458-0.1940.024
call42.000.151.201.100.9572220.000.355-0.1350.023
call43.000.051.001.000.99049.000.000.286-0.1150.021
call44.000.052.200.871.0942010.000.267-0.1230.020
call45.000.051.300.501.2184960.000.248-0.1310.019
call46.000.050.950.001.2630.000.000.232-0.1310.019
call47.000.050.850.001.3240.000.000.206-0.1280.017
call48.000.050.950.001.3980.000.000.198-0.1320.017
call49.000.050.950.001.4710.000.000.190-0.1360.017
call50.000.050.300.201.1549951010.097-0.0670.011
call55.000.000.950.371.4513400.000.081-0.0740.009
call60.000.050.400.091.7162,2795000.071-0.0790.008
call65.000.000.150.431.7306230.000.038-0.0460.005
call70.000.001.750.101.9101,2560.000.036-0.0510.005
call75.000.002.150.052.0998370.000.033-0.0530.005
call80.000.002.000.102.2486540.000.031-0.0540.004
call85.000.002.100.052.3971,2250.000.030-0.0550.004
call90.000.002.100.102.5361900.000.029-0.0560.004
call95.000.000.250.702.6351850.000.028-0.0530.004
call1000.002.150.052.7786580.000.027-0.0580.004
call1050.001.750.372.90099.000.000.026-0.0590.004
call1100.001.850.403.0086500.000.025-0.0600.004
call1150.001.951.723.1101550.000.024-0.0610.004
call1200.001.801.003.2072390.000.024-0.0610.003
call1250.001.950.853.2993.000.000.023-0.0620.003
call1300.001.800.353.3871010.000.023-0.0620.003
call1350.001.551.503.4702.000.000.023-0.0630.003
call1400.001.650.533.55123.000.000.022-0.0640.003
call1450.002.150.363.6288.000.000.022-0.0640.003
call1500.002.150.013.69915.000.000.021-0.0640.003
call1550.002.150.103.78512.000.000.021-0.0650.003
call1600.001.200.103.84216.000.000.021-0.0650.003
put25.000.001.350.002.1780.000.00-0.073-0.1020.008
put26.000.001.550.002.0380.000.00-0.078-0.1000.009
put27.000.001.350.001.8730.000.00-0.084-0.0970.009
put28.000.001.350.001.7420.000.00-0.090-0.0950.010
put29.000.001.550.501.59717.000.00-0.098-0.0930.011
put30.000.050.500.201.3612,0130.00-0.115-0.0860.012
put31.000.001.800.001.8060.000.00-0.176-0.1570.016
put32.000.051.200.001.6420.000.00-0.192-0.1500.017
put33.000.051.301.311.5371.000.00-0.216-0.1510.018
put34.000.051.651.311.5772.000.00-0.251-0.1690.019
put35.000.202.500.921.8056110.00-0.303-0.2120.021
put36.000.202.752.001.7322450.00-0.333-0.2040.022
put37.001.053.401.721.8131251.00-0.373-0.2200.023
put38.000.353.902.611.82028.000.00-0.409-0.2240.024
put39.001.304.400.001.8040.000.00-0.451-0.2100.024
put40.002.404.904.101.7743693.00-0.503-0.1850.024
put41.002.355.500.001.7710.000.00-0.544-0.1900.024
put42.003.106.200.001.7950.000.00-0.644-0.1290.023
put43.003.807.007.451.8361.000.00-0.713-0.1100.021
put44.004.507.906.821.9651.000.00-0.733-0.1180.020
put45.005.808.708.441.9546910.00-0.750-0.1250.019
put46.006.309.700.002.1120.000.00-0.769-0.1270.019
put47.007.2010.600.002.1200.000.00-0.793-0.1220.017
put48.008.1011.500.002.1330.000.00-0.803-0.1270.017
put49.009.5012.500.002.2970.000.00-0.809-0.1310.017
put50.0010.8012.7012.071.9641692.00-0.903-0.0620.011
put55.0015.4018.3016.592.6906621.00-0.919-0.0680.009
put60.0020.6023.3022.002.97463.004.00-0.929-0.0730.008
put65.0025.2028.3028.773.2760.000.00-0.961-0.0420.005
put70.0029.7033.2027.553.56211.000.00-0.964-0.0430.005
put75.0034.7038.2029.003.8060.000.00-0.967-0.0440.005
put80.0039.1043.2033.564.0280.000.00-0.969-0.0450.004
put85.0044.1048.2027.434.2310.000.00-0.970-0.0460.004
put90.0049.1053.2041.104.4440.000.00-0.971-0.0460.004
put95.0054.1058.2026.224.5100.000.00-0.972-0.0470.004
put10059.1063.2049.614.6720.000.00-0.973-0.0470.004
put10564.1068.2033.204.9100.000.00-0.974-0.0470.004
put11069.1073.2038.605.0540.000.00-0.975-0.0480.004
put11574.1078.2042.405.1740.000.00-0.976-0.0480.004
put12079.1083.200.005.3450.000.00-0.976-0.0480.003
put12584.3088.200.005.3510.000.00-0.977-0.0480.003
put13089.6093.200.005.5850.000.00-0.977-0.0480.003
put13594.7098.200.005.6310.000.00-0.977-0.0480.003
put14099.50103.20.005.7750.000.00-0.978-0.0480.003
put145104.8108.20.005.9050.000.00-0.978-0.0480.003
put150109.8113.20.006.1070.000.00-0.979-0.0480.003
put155114.8118.20.006.0970.000.00-0.979-0.0480.003
put160119.9123.20.006.1590.000.00-0.979-0.0480.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-10-20S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-28SCHEDULE 13G/ASEC
2026-09-258-KCurrent report2026-09-24SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-31SCHEDULE 13GSEC
2026-07-29SCHEDULE 13GSEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-17144Filing for proposed sale of securities under Rule 144.SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-16144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080043.48K2
2026-070000
2026-06001.95M4
2026-050042.12K2
2026-040000
2026-030000
2026-020044.02K2
2026-0100137.94K1
2025-120000
2025-1100216.79K3

Institutional holders

Manager% owned
FMR LLC15.00%
Two Seas Capital LP9.80%
BlackRock, Inc.8.71%
BVF INC/IL7.08%
VANGUARD CAPITAL MANAGEMENT LLC4.43%
TWO SIGMA INVESTMENTS, LP3.56%
Vestal Point Capital, LP2.96%
MORGAN STANLEY2.77%
STATE STREET CORP2.69%
GEODE CAPITAL MANAGEMENT, LLC2.61%

Funds

Fund% owned
Fidelity Growth Company Fund5.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
iShares Russell 2000 ETF2.65%
Fidelity Growth Company K6 Fund1.47%
Fidelity Series Growth Company Fund1.24%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Fidelity Small Cap Index Fund1.12%
iShares Russell 2000 Growth ETF0.84%
LORD ABBETT DEVELOPING GROWTH FUND INC0.82%
VANGUARD RUSSELL 2000 INDEX FUND0.58%

OakChart. NKTR. Cached 15 minutes.